Efalizumab-induced autoimmune pancytopenia.
Efalizumab is a recombinant, humanized monoclonal anti-CD11a antibody used for the treatment of moderate to severe plaque psoriasis. Immune-mediated thrombocytopenia and anaemia have previously been reported with this therapy. We describe the first case of immune-mediated pancytopenia in a patient treated with efalizumab. Close monitoring of all blood cell counts is warranted in light of this case.
Tom
W L
WL
Department of Dermatology, Saint Louis University School of Medicine, 1402 South Grand Blvd, MO 63104, USA.
Miller
M D
MD
Hurley
M Y
MY
Suneja
T
T
Kudva
G
G
Leonardi
C L
CL
Obadiah
J M
JM
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000139:chemically induced*; D040881:CD11a Antigen / Q000276:immunology; D003879:Dermatologic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D010198:Pancytopenia / Q000139:chemically induced*; D011565:Psoriasis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D040881:CD11a Antigen; D003879:Dermatologic Agents; C472181:efalizumab